Biogen (BIIB) Non-Current Assets (2009 - 2026)
Biogen (BIIB) posted quarterly Non-Current Assets of $24.8 billion for Q2 2026, up 21.7% year-over-year from $20.4 billion in Q2 2025, and up 22.12% quarter-over-quarter from $20.3 billion in Q1 2026.
Biogen (BIIB) Non-Current Assets (2009 - 2026) Analysis & Trends
Biogen's Non-Current Assets history runs 18 years deep, the most recent figure standing at $24.8 billion for Q2 2026.
- In Q2 2026, Non-Current Assets rose 21.7% year-over-year to $24.8 billion; the TTM figure through Jun 2026 stood at $85.8 billion (up 3.58% YoY), while the FY2025 annual figure was $20.5 billion, down 0.62% from the prior year.
- Non-Current Assets for Q2 2026 stood at $24.8 billion, up from $20.3 billion in the prior quarter.
- The five-year high for Non-Current Assets was $24.8 billion in Q2 2026, with the low at $14.7 billion in Q2 2023.
- The 5-year median for Non-Current Assets is $19.9 billion (2023), against an average of $18.8 billion.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets fell 11.26% in 2022, then soared 35.38% in 2023.
- Biogen's Non-Current Assets stood at $14.8 billion in 2022, then jumped by 35.38% to $20.0 billion in 2023, then grew by 3.04% to $20.6 billion in 2024, then slipped by 0.62% to $20.5 billion in 2025, then rose by 21.09% to $24.8 billion in 2026.
- Business Quant data shows BIIB's Non-Current Assets at $24.8 billion in Q2 2026, $20.3 billion in Q1 2026, and $20.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 24.78 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.78 Bn |
| Mar 31, 2026 | 20.29 Bn |
| Dec 31, 2025 | 20.47 Bn |
| Sep 30, 2025 | 20.27 Bn |
| Jun 30, 2025 | 20.36 Bn |
| Mar 31, 2025 | 20.41 Bn |
| Dec 31, 2024 | 20.59 Bn |
| Sep 30, 2024 | 21.48 Bn |
| Jun 30, 2024 | 19.70 Bn |
| Mar 31, 2024 | 19.81 Bn |
| Dec 31, 2023 | 19.99 Bn |
| Sep 30, 2023 | 19.74 Bn |
| Jun 30, 2023 | 14.73 Bn |
| Mar 31, 2023 | 14.84 Bn |
| Dec 31, 2022 | 14.76 Bn |
| Sep 30, 2022 | 15.09 Bn |
| Jun 30, 2022 | 15.34 Bn |
| Mar 31, 2022 | 15.70 Bn |
| Dec 31, 2021 | 16.02 Bn |
| Sep 30, 2021 | 16.64 Bn |